PP
TEVA icon

Paloma Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Paloma Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-16,000
Closed -$856K – 2339
2016
Q1 		$856K Buy
+16,000
New +$939K 0.01% 977

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Paloma Partners's TEVA Position: Q3 2024 in Review

Paloma Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 14,643 shares — an estimated $238K sold.

Paloma Partners first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $2.2M in Q3 2014. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Paloma Partners reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 14,643 Teva Pharmaceuticals shares in Q3 2024, an estimated $238K.
  • Paloma Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Paloma Partners's Teva Pharmaceuticals position peaked at $2.2M in Q3 2014.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.